The statistic was assembled from several annual reports.
* Transition year (BMS' acquisition of Celgene); value is rounded.
** Year of first generic version on the market.
In 2025, one of the leading cancer drugs globally generated approximately *** U.S. dollars in revenue. Revenues declined sharply following the launch of a generic version of the drug in March 2022. Revlimid was developed by Celgene Corporation, a former company headquartered in Summit, New Jersey. The company specializes in drug manufacturing for cancer and inflammatory disorders. During 2019, the company was acquired by Bristol Myers Squibb.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Bristol-Myers Squibb, & U.S. Securities and Exchange Commission. (February 11, 2026). Revenue of top product Revlimid from 2008 to 2025 (in million U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 29, 2026, from /statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb, und U.S. Securities and Exchange Commission. "Revenue of top product Revlimid from 2008 to 2025 (in million U.S. dollars)." Chart. February 11, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 29, 2026. /statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb, U.S. Securities and Exchange Commission. (2026). Revenue of top product Revlimid from 2008 to 2025 (in million U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 29, 2026. /statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb, and U.S. Securities and Exchange Commission. "Revenue of Top Product Revlimid from 2008 to 2025 (in Million U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 11 Feb 2026, /statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb & U.S. Securities and Exchange Commission, Revenue of top product Revlimid from 2008 to 2025 (in million U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/1269411/revenues-of-revlimid/ (last visited July 29, 2026)
Revenue of top product Revlimid from 2008 to 2025 (in million U.S. dollars) [Graph], Bristol-Myers Squibb, & U.S. Securities and Exchange Commission, February 11, 2026. [Online]. Available: /statistics/1269411/revenues-of-revlimid/
